Phase II Study of Midodrine for Neurogenic Orthostatic Hypotension
OBJECTIVES: I. Study further the safety and efficacy of the alpha-receptor agonist midodrine in patients with neurogenic orthostatic hypotension.
II. Assess the quality of life in these patients with this treatment regimen.
|Study Design:||Primary Purpose: Treatment|
|Study Start Date:||April 2001|
PROTOCOL OUTLINE: This is a partially randomized, multicenter study. Patients receive oral midodrine three times a day during weeks 1 and 3-5, then either oral midodrine or placebo for weeks 6-8.
Quality of life is assessed at weeks 3, 6, and 8.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00004268
|United States, New York|
|Mount Sinai School of Medicine|
|New York, New York, United States, 10029|
|Study Chair:||Horacio Kaufmann||Roberts Pharmaceutical|